NEW YORK, Feb. 11—Deltagen has licensed its mammalian gene function database to Merck, the company said in a statement today.
By the terms of the deal, Merck has non-exclusive access to functional data from 750 genes and some associated intellectual property rights.
Deltagen’s DeltaBase organizes in vivo mammalian gene function information derived from large-scale mouse knockout studies. The database connects phenotypic information from these studies with expression profile data to clarify gene interrelationships and biochemical pathways.
Other database subscribers include Lexicon, GlaxoSmithKline, Pfizer and Vertex.
Financial details of this deal were not disclosed. In 2000, DeltaBase charged Pfizer $15 million for a three-year subscription.Redwood City, Calif.-based Deltagen is publicly owned. The company also is working on a database that will use mouse knockouts to collect gene expression profiles in a range of tissues.